In Palbociclib-resistant breast cancer cells, PARP inhibition combined with a STAT3 specific inhibitor re-sensitized cells to the agent, suggesting that concurrent targeting of DDR mechanisms and the IL6/STAT3 pathway could effectively treat acquired resistance to Palbociclib [211]. Here, PARP1 is linked to breast carcinoma.